DaVita Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Javier J. Rodriguez
- Full Time Employees
- 76,000
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 2000 16th Street Denver CO United States of America 80202
- IPO Date
- Oct 31, 1995
- CIK
- 0000927066
- Website
- davita.com
- Similar Companies
- Business
- DaVita Inc. DaVita Inc. provides kidney care services, primarily dialysis treatments for patients with chronic kidney failure and end-stage kidney disease; operates approximately 2,675 outpatient dialysis centers in the United States serving more than 200,000 patients and 367 centers in 11 other countries serving around 49,400 patients; offers related laboratory services, including routine tests for dialysis patients and other physician-prescribed tests; delivers home-based hemodialysis, hospital inpatient dialysis, and acute inpatient dialysis services; provides integrated kidney care and disease management through DaVita Integrated Kidney Care for risk-based arrangements; conducts clinical research via DaVita Clinical Research since 1985 across pharmaceutical and medical device development; supports nephrologists with technology solutions through DaVita Physician Solutions; and develops innovative health care solutions for kidney disease patients through DaVita Venture Group. The company, incorporated in 1994 and formerly known as DaVita HealthCare Partners Inc. until a 2016 name change, maintains world headquarters in Denver, Colorado, and generates the majority of revenues from Medicare and government-based programs while targeting commercial payers for higher margins; it holds a 37% share of the U.S. dialysis market and operates internationally across regions including Latin America, Europe, and Asia. DaVita Inc. recently expanded internationally through 2024 acquisitions from Fresenius Medical Care for $300 million, adding over 270 clinics in Brazil, Colombia, Chile, and Ecuador to become Latin America's largest dialysis provider; entered new markets in Ecuador and Chile while deepening presence in Colombia; refinanced debt with a new $1.9 billion Term Loan B-2 and $3.5 billion credit facilities including a $2 billion Term Loan A-2 and $1.5 billion revolving facility in 2025; issued $1 billion in senior notes due 2033; and reported Q3 2025 revenues of $3.42 billion amid volume challenges from flu season, Hurricane Helene, and a cyber incident.
Top 5 Non-AI S&P 500 Stock Picks for 2H 2026 That Have Surged in 1H
DaVita Inc (DVA) Stock Up 3.0% but GF Value Says Overvalued -- GF Score: 88/100
Should Value Investors Buy DaVita (DVA) Stock?
Best Growth Stocks to Buy for July 2nd
DaVita Stock Benefits From Strengthening Kidney Care Delivery
Best Growth Stocks to Buy for June 30th
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
Why the Market Dipped But DaVita HealthCare (DVA) Gained Today
If You Own These 10 Stocks — Analysts Think You Should Sell Them
Best Growth Stocks to Buy for June 26th
DaVita HealthCare (DVA) Ascends While Market Falls: Some Facts to Note
DaVita Stock Benefits From Expanding Community-Based Kidney Care
Best Growth Stocks to Buy for June 24th
DVA vs. FMS: Which Dialysis Leader Is Better Positioned Now?
3 Medical Stocks to Bet on Amid Market Optimism Following SpaceX IPO
Best Growth Stocks to Buy for June 22nd
DaVita HealthCare (DVA) Stock Dips While Market Gains: Key Facts
4 Stocks Trading Near 52-Week High With Room to Rise Further
DaVita Expands Specialized Care Beyond Acute Settings Through IKC
Best Value Stocks to Buy for June 17th